What to do with targeted IL-2

Drugs of Today

Volumn 36, Issue 5, 2000, Pages 321-336

  Lode, Holger N ^a   Xiang, Rong ^a   Perri, Patrizia ^b   Pertl, Ursula ^a   Lode, Axel ^a   Gillies, Stephen D ^c   Reisfeld, Ralph A ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c Lexigen Pharmaceuticals Corp   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; CANCER VACCINE; CD8 ANTIGEN; HYBRID PROTEIN; RECOMBINANT ANTIBODY; RECOMBINANT INTERLEUKIN 2;

BONE MARROW METASTASIS; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; COLORECTAL CARCINOMA; DRUG EFFICACY; DRUG POTENTIATION; DRUG TARGETING; ERADICATION THERAPY; HUMAN; LIVER METASTASIS; MELANOMA; MEMORY CELL; NEUROBLASTOMA; NONHUMAN; REVIEW; T LYMPHOCYTE SUBPOPULATION;

EID: 0034069669     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2000.36.5.575044     Document Type: Review

References (82)

1. Silverstein, A.M. A history of immunology. Jovanovich, H.B. (Ed.). Academic Press Inc.: San Diego 1988, 1-383.
2. Kohler, G., Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975, 256: 495-7.
3. Maloney, D.G., Lues, T.M., Czerwinski, D.K. et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994, 84: 2457-66.
4. Maloney, D.G., Brown, S., Czerwinski, D.K. et al. Monoclonal anti-idiotype antibody therapy of B-cell lymphoma: The addition of a short course of chemotherapy does not interfere with the antitumor effect nor prevent the emergence of idiotype-negative variant cells. Blood 1992, 80: 1502-10.
5. Riethmuller, G., Schneider-Gadicke, E., Schlimok, G. et al. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group Lancet 1994, 343: 1177-83.
6. 2 antibody 14.G2a. Cancer Immunol Immunother 1992, 35: 199-204.
7. Handgretinger, R., Anderson, K., Lang, P. et al. A phase I study of human/mouse chimeric anti-ganglioside GD2 antibody ch14.18 in patients with neuroblastoma. Eur J Cancer 1995, 31A: 261-7.
8. Niethammer, D., Handgretinger, R. Clinical strategies for the treatment of neuroblastoma. Eur J Cancer 1995, 31A: 568-71.
9. 2 antibody 14G2a in metastatic melanoma. Cancer Res 1992, 52: 4342-7.
10. Murray, J.L., Cunningham, J.E., Brewer, H. et al. Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors. J Clin Oncol 1994, 12: 184-93.
11. 2. Proc Natl Acad Sci USA 1986, 83: 8694-8.
12. 2 antibody 14.G2a plus IL-2 in children with refractory neuroblastoma: A report of the Children's Cancer Group. Cancer 1997, 80: 317-33.
13. Bajorin, D.F., Chapman, P.B., Wong, G. et al. Phase I evaluation of a combination of monoclonal antibody R24 and interleukin 2 in patients with metastatic melanoma. Cancer Res 1990, 50: 7490-5.
14. Rosenberg, S.A., Yannelli, J.R., Yang, J.C. et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 1994, 86: 1159-66.
15. Rosenberg, S.A., Lotze, M.T., Yang, J.C. et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989, 210: 474-85.
16. Rosenberg, S.A., Packard, B.S., Aebersold, P.M. et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. New Engl J Med 1988, 319: 1676-80.
17. Winkelhake, J.L., Gauny, S.S. Human recombinant interleukin-2 as an experimental therapeutic. Pharmacol Rev 1990, 42: 1-28.
18. Maas, R.A., Dullens, H.F., Den Otter, W. Interleukin-2 in cancer treatment: Disappointing or (still) promising? A review. Cancer Immunol Immunother 1993, 36: 141-8.
19. Grimm, E.A., Mazumder, A., Zhang, H.Z., Rosenberg, S.A. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 1982, 155: 1823-41.
20. Grimm, E.A., Ramsey, K.M., Mazumder, A., Wilson, D.J., Djeu, J.Y., Rosenberg, S.A. Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells. J Exp Med 1983, 157: 884-97.
21. Hank, J.A., Robinson, R.R., Surfus, J. et al. Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2. Cancer Res 1990, 50: 5234-9.
22. Pardoll, D.M. Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol 1995, 13:399-415.
23. Roth, J.A., Cristiano, R.J. Gene therapy for cancer: What have we done and where are we going? J Natl Cancer Inst 1997, 89: 21-39.
24. Schwinghammer, T.L., Bloom, E.J. Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation. Clin Pharm 1993, 12: 736-61.
25. Parkman, R. Is chronic graft versus host disease an autoimmune disease? Curr Opin Immunol 1993, 5: 800-3.
26. 2 antibody. Hybridoma 1991, 10: 347-56.
27. Gillies, S.D., Reilly, E.B., Lo, K.M., Reisfeld, R.A. Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells. Proc Natl Acad Sci USA 1992, 89: 1428-32.
28. Hornick, J.L., Khawli, L.A., Hu, P., Lynch, M., Anderson, P.M., Epstein, A.L. Chimeric CLL-1 antibody fusion proteins containing granulocyte-macrophage colony-stimulating factor or interleukin-2 with specificity for B-cell malignancies exhibit enhanced effector functions while retaining tumor targeting properties. Blood 1997, 89: 4437-47.
29. Tao, M.H., Levy, R. Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature 1993, 362: 755-8.
30. Chen, T.T., Tao, M.H., Levy, R. Idiotype-cytokine fusion proteins as cancer vaccines. Relative efficacy of IL-2, IL-4, and granulocyte-macrophage colony-stimulating factor. J Immunol 1994, 153: 4775-87.
31. Xiang, R., Lode, H.N., Dolman, C.S. et al. Elimination of established murine colon carcinoma metastases by antibody-interleukin 2 fusion protein therapy. Cancer Res 1997, 57: 4948-55.
32. Sabzevari, H., Gillies, S.D., Mueller, B.M., Pancook, J.D., Reisfeld, R.A. A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice. Proc Natl Acad Sci USA 1994, 91: 9626-30.
33. Becker, J.C., Pancook, J.D., Gillies, S.D., Furukawa, K., Reisfeld, R.A. T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy. J Exp Med 1996, 183: 2361-6.
34. Becker, J.C., Varki, N.M., Gillies, S.D., Furukawa, K., Reisfeld, R.A. An antibody-interleukin 2 fusion protein overcomes tumor heterogeneity by induction of a cellular immune response. Proc Natl Acad Sci USA 1996, 93: 7826-31.
35. Becker, J.C., Varki, N.M., Gillies, S.D., Furukawa, K., Reisfeld, R.A. Long-lived and transferable tumor immunity in mice after targeted interleukin-2 therapy. J Clin Invest 1997, 98: 2801-4.
36. Steimle, S. Experts call for action to prevent colon cancer deaths by spurring screening awareness. J Natl Cancer Inst 1997, 89: 415-6.
37. Huang, A.Y., Gulden, P.H., Woods, A.S. et al. The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc Natl Acad Sci USA 1996, 93: 9730-35.
38. Lode, H.N., Xiang, R., Becker, J.C., Gillies, S.D., Reisfeld, R.A. Immunocytokines: A promising approach to cancer immunotherapy. Pharmacol Ther 1998, 80: 277-92.
39. Xiang, R., Lode, H.N., Dreier, T., Gillies, S.D., Reisfeld, R.A. Induction of persistent tumor-protective immunity in mice cured of established colon carcinoma metastases. Cancer Res 1998, 58: 3918-25.
40. Xiang, R., Lode, H.N., Gillies, S.D., Reisfeld, R.A. T cell memory against colon carcinoma is long lived in the absence of antigen. J Immunol 1999, 163: 3676-83.
41. Sprent, J. Antigen-presenting cells. Professionals and amateurs. Curr Biol 1995, 5: 1095-7.
42. Maass, G., Schmidt, W., Berger, M. et al. Priming of tumor-specific T cells in the draining lymph nodes after immunization with interleukin 2-secreting tumor cells: Three consecutive stages may be required for successful tumor vaccination. Proc Natl Acad Sci USA 1995, 92: 5540-4.
43. Lode, H.N., Xiang, R., Varki, N.M., Dolman, C.S., Gillies, S.D., Reisfeld, R.A. Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow. J Natl Cancer Inst 1997, 89: 1586-94.
44. Castleberry, R.P. Predicting outcome in neuroblastoma. New Engl J Med 1999, 340: 1992-3.
45. Berthold, F., Sahin, K., Hero, B. et al. The current contribution of molecular factors to risk estimation in neuroblastoma patients. Eur J Cancer 1997, 33: 2092-7.
46. Brodeur, G.M., Seeger, R.C., Schwab, M., Varmus, H.E., Bishop, J.M. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984, 224: 1121-4.
47. Weiss, W.A., Aldape, K., Mohapatra, G., Feuerstein, B.G., Bishop, J.M. Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J 1997, 16: 2985-95.
48. Schwab, M., Alitalo, K., Klempnauer, K.H. et al. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature 1983, 305: 245-8.
49. Lode, H.N., Bruchelt, G., Seitz, G. et al. Reverse transcriptase-polymerase chain reaction (RT-PCR) analysis of monoamine transporters in neuroblastoma cell lines: Correlations to meta-iodobenzylguanidine (MIBG) uptake and tyrosine hydroxylase gene expression. Eur J Cancer 1995, 31A: 586-90.
50. 131I MIBG therapy in neuroblastoma: Mechanisms, rationale, and current status. Med Pediatr Oncol 1999, 32: 427-31.
51. Perel, Y., Conway, J., Kletzel, M. et al. Clinical impact and prognostic value of meta-iodoben-zylguanidine imaging in children with metastatic neuroblastoma. J Pediatr Hematol Oncol 1999, 21: 13-8.
52. 131I-meta-iodo-benzylguanidine, high-dose chemotherapy and immunotherapy. A pilot study. Eur J Cancer 1998, 34: 1398-402.
53. 131l-meta-iodobenzylguanidine in the treatment of neuroblastoma. Med Pediatr Oncol 1998, 31: 22-6.
54. Lode, H.N., Xiang, R., Dreier, T., Varki, N.M., Gillies, S.D., Reisfeld, R. Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy. Blood 1998, 91: 1706-15.
55. Raulet, D.H. Recognition events that inhibit and activate natural killer cells. Curr Opin Immunol 1996, 8: 372-7.
56. Raulet, D.H., Held, W. Natural killer cell receptors: The offs and ons of NK cell recognition. Cell 1995, 82: 697-700.
57. Gumperz, J.E., Parham, P. The enigma of the natural killer cell. Nature 1995, 378: 245-8.
58. Massague, J. The TGF-β family of growth and differentiation factors. Cell 1987, 49: 437-8.
59. Roszman, T., Elliott, L., Brooks, W. Modulation of T-cell function by gliomas. Immunol Today 1991, 12: 370-4.
60. Ruffini, P.A., Rivoltini, L., Silvani, A., Boiardi, A., Parmiani, G. Factors, including transforming growth factor β, released in the glioblastoma residual cavity, impair activity of adherent lymphokine-activated killer cells. Cancer Immunol Immunother 1993, 36: 409-16.
61. Schwartz, R.H. Models of T cell anergy: Is there a common molecular mechanism ? J Exp Med 1996, 184: 1-8.
62. Smith, K.A. Lowest dose interleukin-2 immunotherapy. Blood 1993, 81: 1414-23.
63. Tigges, M.A., Casey, L.S., Koshland, M.E. Mechanism of interleukin-2 signaling: Mediation of different outcomes by a single receptor and transduction pathway. Science 1989, 243: 781-6.
64. Carson, W.E., Lindemann, M.J., Baiocchi, R. et al. The functional characterization of interleukin-10 receptor expression on human natural killer cells. Blood 1995, 85: 3577-85.
65. Zheng, L.M., Ojcius, D.M., Garaud, F. et al. Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism. J Exp Med 1996, 184: 579-84.
66. Van Schooten, W.C., Strang, G., Palathumpat, V. Biological properties of dendritic cells: Implications to their use in the treatment of cancer. Mol Med Today 1997, 3: 254-60.
67. Pardoll, D.M. Cancer vaccines. Nat Med 1998, 4: 525-31.
68. Weber, L.W., Bowne, W.B., Wolchok, J.D. et al. Tumor immunity and autoimmunity induced by immunization with homologous DNA. J Clin Invest 1998, 102: 1258-64.
69. Rosenberg, S.A., Yang, J.C., Schwartzentruber, D.J. et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998, 4: 321-7.
70. Lode, H.N., Dreier, T., Xiang, R., Varki, N.M., Kang, A.S., Reisfeld, R.A. Gene therapy with a single chain interleukin 12 fusion protein induces T cell-dependent protective immunity in a syngeneic model of murine neuroblastoma. Proc Natl Acad Sci USA 1998, 95: 2475-80.
71. Lode, H.N., Xiang, R., Duncan, S.R., Theofilopoulos, A.N., Gillies, S.D., Reisfeld, R.A. Tumor-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL-12. Proc Natl Acad Sci USA 1999, 96: 8591-6.
72. Holmgren, L., O'Reilly, M.S., Folkman, J. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995, 1: 149-53.
73. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995, 1: 27-31.
74. O'Reilly, M.S., Holmgren, L., Shing, Y. et al. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994, 79: 315-28.
75. Kerbel, R.S. A cancer therapy resistant to resistance. Nature 1997, 390: 335-6.
76. Boehm, T., Folkman, J., Browder, T., O'Reilly, M.S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997, 390: 404-7.
77. Volpert, O.V., Lawler, J., Bouck, N.P. A human fibrosarcoma inhibits systemic angiogenesis and the growth of experimental metastases via thrombospondin-1. Proc Natl Acad Sci USA 1998, 95: 6343-8.
78. 3 for angiogenesis. Science 1994, 264: 569-71.
79. v integrins. Science 1995, 270: 1500-2.
80. vβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994, 79: 1157-64.
81. v antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases. Proc Natl Acad Sci USA 1999, 96: 1591-6.
82. Mauceri, H.J., Hanna, N.N., Beckett, M.A. et al. Combined effect of angiostatin and ionizing radiation in antitumor therapy. Nature 1998, 394: 287-91.